Short Interest in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Declines By 17.5%

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the target of a large drop in short interest in March. As of March 13th, there was short interest totaling 2,305 shares, a drop of 17.5% from the February 26th total of 2,795 shares. Based on an average daily volume of 11,098 shares, the short-interest ratio is currently 0.2 days. Approximately 0.2% of the shares of the stock are short sold.

Institutional Trading of Global X Genomics & Biotechnology ETF

Several institutional investors and hedge funds have recently made changes to their positions in GNOM. IFP Advisors Inc boosted its stake in shares of Global X Genomics & Biotechnology ETF by 20.8% during the third quarter. IFP Advisors Inc now owns 2,835 shares of the company’s stock valued at $110,000 after acquiring an additional 489 shares during the last quarter. Smartleaf Asset Management LLC raised its stake in Global X Genomics & Biotechnology ETF by 30.9% in the 2nd quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock valued at $164,000 after purchasing an additional 4,615 shares during the last quarter. Sei Investments Co. raised its stake in Global X Genomics & Biotechnology ETF by 110.4% in the 2nd quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock valued at $194,000 after purchasing an additional 12,105 shares during the last quarter. Creative Financial Designs Inc. ADV lifted its holdings in Global X Genomics & Biotechnology ETF by 4.1% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 12,124 shares of the company’s stock valued at $551,000 after purchasing an additional 481 shares in the last quarter. Finally, U.S. Capital Wealth Advisors LLC purchased a new position in Global X Genomics & Biotechnology ETF in the 4th quarter valued at about $575,000. 56.95% of the stock is currently owned by hedge funds and other institutional investors.

Global X Genomics & Biotechnology ETF Stock Performance

GNOM stock opened at $41.50 on Monday. The stock’s 50 day moving average price is $46.13 and its 200 day moving average price is $44.58. The firm has a market cap of $45.24 million, a P/E ratio of -17.74 and a beta of 1.22. Global X Genomics & Biotechnology ETF has a 1 year low of $27.20 and a 1 year high of $51.42.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.